Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOG-0281 trametinib versus standard treatment in recurrent low-grade serous ovarian or peritoneal cancer
2013-001627-39Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in low-grade serous ovarian carcinoma (LGSOC) and primary peritoneal cancer (PPC) comparing Trametinib with Standard of care / physician's choice (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
trametinib
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2013-001627-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001627-39.